Epzicom Conference Citations

Medical Advocates
Abacavir/Lamivudine (Epzicom)

Conference Citations

XVII International AIDS Conference
15th CROI
8th Int Congress on Drug Therapy in HIV Infection
XVI International AIDS Conference
13th CROI
3rd IAS Conference
XV International AIDS Conference
XIV International AIDS Conference

Epzicom Main Page Main New/Newsworthy Home Page

Last Updated: August 08, 2008
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

XVII International AIDS Conference

NEWS RELEASE
Analysis of Six Clinical Trials Finds EPZICOM Effective in Treatment-Naive HIV Patients
With Both High and Low Baseline Viral Loads
GSK August 07, 2008
NEWS RELEASE
Head-to-Head 96-Week Study Shows EPZICOM is Comparable to Truvada in Efficacy and Safety Measures in
HIV Treatment-Naive Patients
GSK August 07, 2008

15th Conference on Retroviruses and
Opportunistic Infections

Efficacy and Safety of Abacavir/Lamivudine Compared to Tenofovir/Emtricitabine in
Combination with Once-daily Lopinavir/Ritonavir through 48 Weeks in the HEAT Study
K Smith, D Fine, P Patel, et al
Abstract

4th IAS Conference on HIV Pathogenesis, Treatment
and Prevention

Once-daily abacavir/lamivudine (ABC/3TC) and boosted atazanavir (ATV/RTV) in antiretroviral-naive
HIV-1 infected subjects: 48-week results from COL102060 (SHARE)
Elion R, DeJesus E, Sension M, et al
Abstract

8th Int Congress on Drug Therapy in HIV Infection

Switching from twice daily (BID) abacavir (ABC) and lamivudine (3TC) to a fixed dose
combination (FDC) of ABC/3TC taken once daily (QD) improves patient adherence and
satisfaction with therapy
D Maitland, A Jackson, J Osorio, et al
Abstract
ABC/3TC in combination with a boosted PI in clinical practice
A Carganico, S Dupke, B Hintsche, et al
Abstract
Once-daily (QD) abacavir (ABC)/lamivudine (3TC) and ritonavir-boosted atazanavir (ATV/r)
in antiretroviral na�ve HIV-1infected subjects: 24-week analysis from COL102060 (SHARE)
R Elion, E DeJesus, M Sension, et al
Abstract

XVI International AIDS Conference

Switching from twice daily (BID) abacavir (ABC) and lamivudine (3TC) to a fixed dose
combination (FDC) of ABC/3TC taken once daily (QD) improves patient adherence and
satisfaction with therapy
Maitland D., Jackson A., Osorio J
Abstract

13th Conference on Retroviruses and
Opportunistic Infections

POSTER
A Randomized Trial of Early vs Delayed Fixed-dose Combination Zidovudine/Lamivudine/Abacavir
in Patients Co-infected with HIV and Tuberculosis: Early Findings of the Tuberculosis and HIV
Immune Reconstitution Syndrome Trial
H Shao, J Crump, H Ramadhani, et al
PDF Poster Abstract

3rd IAS Conference

POSTER
Safety of Abacavir (ABC)+Lamivudine (3TC)-based HAART in ART-Na�ve HIV-Infected Subjects
With and Without Hepatitis B (HBV) and/or Hepatitis C (HCV) Co-Infection.
H Zhao, et al
PDF Poster

Efficacy and safety of a once daily fixed-dose combination of abacavir/lamivudine (ABC/3TC) [FDC ]
versus ABC twice daily and 3TC once daily as separate entities [SE] in ART-experienced HIV-1
infected subjects (CAL30001): 48 week data.
Clumeck N., LaMarca A., Fu K., et al
Abstract

Efficacy and Safety of Once-Daily Abacavir/Lamivudine Fixed-Dose Combination (ABC/3TC) +
Efavirenz (EFV): ESS30009 Planned 48 Week Analysis.
Gallant J., Rodriguez A., Weinberg W. et al
Abstract

Reported Incidence and Severity of Suspected Abacavir Hypersensitivity Reactions (HSR)
through at least 6 Weeks in a Large, Controlled Clinical Trial Using a Once-Daily (OAD)
abacavir 600mg/lamivudine 300mg tablet (ABC/3TC FDC) Dual Nucleoside Backbone with
a Boosted Protease Inhibitor: The KLEAN Study
Becker S., Yeni P., Sutherland-Phillips D., et al
Abstract

Patient satisfaction with abacavir (ABC)-lamivudine (3TC) fixed dose combination (FDC) tablet
once daily (QD) compared with ABC and 3TC twice daily (BID) in HIV-1 infected patients
ESS30008)
Watson M., Hill-Zabala C., Sosa N., et al
Abstract

XV International AIDS Conference

96 Week lipids and anthropometrics for subjects receiving initial therapy with
abacavir+lamivudine (ABC+3TC) combined with efavirenz (NNRTI), amprenavir/ritonavir (PI)
or stavudine (NRTI): ESS40001(CLASS)
K Sathasivam, SK Griffith, JA Bartlett, et al
Abstract
Initial therapy with Abacavir+ Lamivudine (ABC+3TC) combined with Efavirenz (NNRTI),
Amprenavir/Ritonavir (PI) or Stavudine (NRTI): ESS40001(CLASS)
JA Bartlett, J Johnson, G Herrer, et al
Abstract

XIV International AIDS Conference

Abacavir/Lamivudine (ABC/3TC) in combination with Efavirenz (NNRTI), Amprenavir/Ritonavir (PI)
or Stavudine (NRTI): ESS40001(CLASS) preliminary 48 week results
J Bartlett, J Johnson, G Herrera, et al
Abstract

Epzicom Main Page Main New/Newsworthy Home Page

Abacavir/ Fixed Dose Lamivudine (Epzicom)
Conference Citations